TOP - December 2012 VOL 5, NO 8 published on December 20, 2012 in Rare Cancers
Interest in pancreatic neuroendocrine tumors (pNETs) has grown since the recent approval of targeted agents for advanced disease, as was evident by the attendance at several sessions during the European Society for Medical Oncology (ESMO) 2012 Congress in Vienna, Austria.1
TON - November 2012, Vol 5, No 10 published on November 21, 2012 in Rare Cancers
Interest in pancreatic neuroendocrine tumors (pNETs) has grown since the recent approval of targeted agents for advanced disease, as was evident by the attendance at several sessions during the European Society for Medical Oncology (ESMO) 2012 Congress in Vienna, Austria.1
TON - March 2017, Vol 10, No 2 published on March 7, 2017 in Rare Cancers
By improving chemotherapy-induced peripheral neuropathy (CIPN), administration of duloxetine may enable patients with advanced pancreatic cancer to continue their treatment regimen of gemcitabine plus nab-paclitaxel.
TOP - Daily published on August 30, 2011 in Rare Cancers

 

TON July 2016 Vol 9 No 4 published on July 18, 2016 in Rare Cancers
Although it is a rare disorder, approximately 14,000 new cases of sarcoma are diagnosed in the United States each year.
TON - October 2010, Vol. 3, No 7 published on October 22, 2010 in Rare Cancers

CHICAGO—Patients with myelodysplastic syndromes (MDS) treated with hypomethylating agents (HMAs), especially decitabine, are more likely to achieve hematologic responses when treated with a greater number of cycles, investigators from Georgia Cancer Specialists in Marietta reported at the 2010 annual meeting of the American Society of Clinical Oncology.

TON - Other published on May 6, 2011 in Rare Cancers

Pancreatic neuroendocrine tumor (PNET) refers to several tumor types located in the pancreas. These tumors are classified as functional or nonfunctional depending on production and secretion of bioactive hormones. Functional PNETs cause clinical symptoms associated with their tumor classification.

TOP - May 2014, Vol 7, No 2 published on June 10, 2014 in Rare Cancers
A dual vaccine strategy improved survival more than single vaccination of patients with metastatic pancreatic ductal adenocarcinoma (PDAC). Data from a randomized phase 2 trial were reported by Dung T. Le, MD, at the 2014 Gastrointestinal Cancers Symposium.
TON - August 2013 Vol 6 No 7 published on September 4, 2013 in Rare Cancers
Sorafenib has become the first drug in years to prove effective in the treatment of differentiated thyroid cancer (DTC) that has become resistant to radioactive iodine (RAI), according to phase 3 study results reported at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting.

Results 1 - 9 of 9